Selection of Microbial T-Cell Epitopes for Immune-Diagnosis, Immune- Therapy and Vaccine Design
The ability to induce and/or monitor an immune response to a broad repertoire of epitopes universally recognized across continents and genetic backgrounds is considered a critical characteristic of an effective vaccine and diagnostic tool. Opportunities for epitope identification are expanding as the number of entirely sequenced pathogens approaches 500 and access to this data improves. The pace of vaccine design will accelerate as bioinformatics are systematically applied to whole genomes and used in combination with in vitro methods for screening and confirming epitopes. Given access to bioinformatic tools, epitope-driven diagnostic tools and both preventive and therapeutic vaccines (for infectious diseases of worldwide impact such as tuberculosis and HIV) are now within our reach. This review describes the structural basis of the bioinformatic tools for epitope prediction methods as well as the recent use of these approaches at genomic level in the development of diagnostic tools and vaccine design as example of structural bioinformatic system applied to pharmacogenomics.
No Supplementary Data
No Article Media
Document Type: Review Article
Affiliations: Department of Internal Medicine, University of Rome "Tor Vergata", Via Montpellier 1, I-00133 Rome, Italy.
Publication date: December 1, 2005
More about this publication?
- Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.
The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites